These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 8669855

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M, Hippeläinen M, Kettunen J, Salmela E, Penttilä I, Alhava E.
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [Abstract] [Full Text] [Related]

  • 5. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA, Kauppinen R, Eskelinen M, Partanen K, Pikkarainen P, Alhava E.
    Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
    Eskelinen M, Pasanen P, Janatuinen E, Pettersson N, Linnane A, Alhava E.
    Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
    [Abstract] [Full Text] [Related]

  • 8. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [Abstract] [Full Text] [Related]

  • 9. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
    Pasanen P, Eskelinen M, Kulju A, Penttilä I, Janatuinen E, Alhava E.
    Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
    [Abstract] [Full Text] [Related]

  • 10. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
    Eskelinen M, Pasanen P, Kulju A, Janatuinen E, Miettinen P, Poikolainen E, Tarvainen R, Nuutinen P, Pääkkönen M, Alhava E.
    Anticancer Res; 1994 Apr; 14(3B):1427-32. PubMed ID: 8067718
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 13. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV, Edwards R, Ho S, Lau WY, Glazer G.
    Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
    [Abstract] [Full Text] [Related]

  • 14. Fluctuations of tumor markers in heart failure patients pre and post heart transplantation.
    Nägele H, Bahlo M, Klapdor R, Rödiger W.
    Anticancer Res; 1999 Aug; 19(4A):2531-4. PubMed ID: 10470189
    [Abstract] [Full Text] [Related]

  • 15. Differential diagnosis between benign and malignant biliary tract obstruction: discriminative usefulness of some clinical and laboratory data.
    Giusti G, Piccinino F, Sagnelli E, Pasquale G.
    Acta Hepatogastroenterol (Stuttg); 1975 Dec; 22(6):374-9. PubMed ID: 1211064
    [Abstract] [Full Text] [Related]

  • 16. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y, Okusaka T, Ueno H, Ikeda M, Morizane C, Najima M.
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [Abstract] [Full Text] [Related]

  • 17. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M, Kataja V, Hämäläinen E, Kosma VM, Penttilä I, Alhava E.
    Anticancer Res; 1997 Sep; 17(2B):1231-4. PubMed ID: 9137478
    [Abstract] [Full Text] [Related]

  • 18. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].
    Basso D, Fabris C, Del Favero G, Panucci A, Piccoli A, Plebani M, Pedrazzoli S, Baccaglini U, Lise M, Burlina A.
    Minerva Med; 1986 Apr 14; 77(16):613-6. PubMed ID: 3458035
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
    Nicolini A, Ferdeghini M, Colombini C, Carpi A.
    J Nucl Med Allied Sci; 1990 Apr 14; 34(4):309-13. PubMed ID: 2090796
    [Abstract] [Full Text] [Related]

  • 20. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT, Tao HQ, Zou SC.
    Hepatobiliary Pancreat Dis Int; 2004 Aug 14; 3(3):464-8. PubMed ID: 15313690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.